



November 2022

Dear Member,

The following pharmacy benefit changes will go into effect January 1, 2023:

- **Formulary GLP-1 Receptor Agonists:** Formulary GLP-1 receptor agonists (i.e., Ozempic, Trulicity, Victoza, Rybelsus) will have [Step Therapy](#) added on the Group Value and Group Choice Formulary.
- **Member Choice Program:** Traditional formulary branded drugs with an equivalent generic will be added to the [Member Choice Program](#). This program is applicable to the Group Value Formulary.
- **BSW Employee Chronic and Preventive List:** Respiratory and anticoagulant medications will be removed from the [Chronic and Preventive List](#) in 2023; however, they will continue to be covered by the plan at the applicable formulary copay. This update will impact the Group Value formulary and applies to SEQA, EQA and PPO plans.

Formulary GLP-1 Receptor Agonists:

Step Therapy helps ensure both cost-effective and clinically effective treatment. The plan wants you to try a Step 1 medication first. Step 1 medications for GLP-1 receptors are metformin or a metformin combination product. If a Step 1 medication doesn't work after 90 days, you can move up to a Step 2 medication. If you have already tried a Step 1 medication for at least 90 days, you will be able to fill your Step 2 medication(s). If you have previously taken a Step 1 medication and it was not effective, or your doctor wants you to keep taking your Step 2 medication(s), your doctor will need to provide information regarding your need for the Step 2 medication(s).

Step 1 medications usually cost less and may be used for the same medical conditions as Step 2 medications.

Member Choice Program:

The Member Choice program encourages members and providers to make cost-effective medication choices. With this program, if you or your provider request a brand-name drug when a generic equivalent is available, you become responsible for the non-preferred co-pay plus the difference in cost between the brand name drug and the generic equivalent. The difference in cost does not apply to any deductible or out-of-pocket maximum for the plan.

For HSA members, the full deductible must be met first before the non-preferred (Tier 3) cost share will apply.

BSW Employee Chronic and Preventive List:

Respiratory and anticoagulant medications will be removed from BSW Employee Chronic and Preventive List in 2023; however, members may continue filling these prescriptions at the formulary preferred brand (Tier 2) or non-preferred brand (Tier 3) copay. The following is a list of medications that are impacted by this change:

ANTICOAGULANTS
ELIQUIS
XARELTO
XARELTO STARTER PACK

RESPIRATORY	
ADVAIR HFA	INCRUSE ELLIPTA
ANORO ELLIPTA	PULMICORT FLEXHALER
ARCAPTA NEOHALER	QVAR
ASMANEX HFA	QVAR REDIHALER
ASMANEX TWISTHALER	SEREVENT DISKUS
ATROVENT HFA	SPIRIVA HANDIHALER
BREO ELLIPTA	SPIRIVA RESPIMAT
COMBIVENT RESPIMAT	STIOLTO RESPIMAT
FLOVENT DISKUS	SYMBICORT
FLOVENT HFA	TRELEGY ELLIPTA

Letter notifications to members impacted by these changes were mailed in early November 2022. Please talk to your doctor as soon as possible to make sure there is no delay in receiving the medication(s) impacted by these changes.

If you have any questions about these changes or your prescription benefits, please call the Customer Service phone number on the back of your ID card.

Be safe and well,

Baylor Scott & White Health Plan

Visit the member portal at
Member.BSWHealth.com

© 2022 Baylor Scott & White Health Plan
 1206 West Campus Drive | Temple, Texas 76502

[Manage your preferences or unsubscribe](#)